Literature DB >> 9480721

Ro/SS-A and La/SS-B antibody level variation in patients with Sjögren's syndrome and systemic lupus erythematosus.

M Wahren1, P Tengnér, I Gunnarsson, I Lundberg, E Hedfors, N R Ringertz, I Pettersson.   

Abstract

To examine both possible correlations between anti-Ro/SS-A and anti-La/SS-B levels and their correlation with clinical disease activity in patients with Sjögren's syndrome (SS) or systemic lupus erythematosus (SLE), an ELISA was developed using purified recombinant Ro 60 kDa, Ro 52 kDa and La antigens. The ELISA was used for testing sequential serum samples from 16 patients with either SS or SLE. The patients were followed for periods between 15 and 128 months, and 3-15 serum samples per patient were analysed and compared with clinically apparent disease activity at the time of sampling in 14 patients. A temporal correlation of antibody levels to Ro and La antigens was found, and antibodies to different epitopes of the Ro 60 kDa protein showed parallel variation in seven of eight patients tested. Co-variation of autoantibody levels and disease activity was found in 11 of 14 patients. In seven of these 11 patients the anti-Ro and anti-La levels were stable and changes in disease activity were minimal during the observation period. In the other four of these 11, changes in disease activity were noted, with an associated change in autoantibody levels. The results suggest that the serological response to Ro and La antigens, as well as to different epitopes of the Ro 60 kDa protein, is antigen driven and regulated by common mechanisms, and indicate a correlation of Ro and La antibodies with pathogenic events. Copyright 1998 Academic Press Limited.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9480721     DOI: 10.1006/jaut.1997.0173

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  15 in total

Review 1.  Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful.

Authors:  Tri Giang Phan; Richard C W Wong; Stephen Adelstein
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

2.  Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies.

Authors:  D Villalta; N Bizzaro; S Platzgummer; A Antico; M Tampoia; L Camogliano; D Bassetti; M Pradella; A Piazza; F Manoni; R Tozzoli; E Tonutti
Journal:  Clin Rheumatol       Date:  2004-12-10       Impact factor: 2.980

Review 3.  TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity.

Authors:  Ricardo Rajsbaum; Adolfo García-Sastre; Gijs A Versteeg
Journal:  J Mol Biol       Date:  2013-12-12       Impact factor: 5.469

4.  Anti-Ro52 autoantibodies from patients with Sjögren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface.

Authors:  Alexander Espinosa; Janosch Hennig; Aurélie Ambrosi; Madhanagopal Anandapadmanaban; Martina Sandberg Abelius; Yi Sheng; Filippa Nyberg; Cheryl H Arrowsmith; Maria Sunnerhagen; Marie Wahren-Herlenius
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

5.  Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease.

Authors:  L M Helenius; J H Hietanen; I Helenius; H Kautiainen; H Piirainen; L Paimela; M Lappalainen; R Suuronen; C Lindqvist; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

6.  Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.

Authors:  J-E Gottenberg; M Busson; J Cohen-Solal; F Lavie; K Abbed; R P Kimberly; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

7.  Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.

Authors:  Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-03       Impact factor: 4.794

8.  Clinical and serological features of patients with autoantibodies to GW/P bodies.

Authors:  Rahima A Bhanji; Theophany Eystathioy; Edward K L Chan; Donald B Bloch; Marvin J Fritzler
Journal:  Clin Immunol       Date:  2007-09-17       Impact factor: 3.969

9.  Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block.

Authors:  L Strandberg; O Winqvist; S-E Sonesson; S Mohseni; S Salomonsson; K Bremme; J P Buyon; H Julkunen; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

Review 10.  Anti-DNA antibodies--quintessential biomarkers of SLE.

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.